PDSB Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
6.5M
-2.3%
6.7M
-18.0%
8.1M
+6.8%
7.6M
-16.3%
9.1M
R&D
3.5M
-21.5%
4.4M
-3.7%
4.6M
+8.6%
4.2M
-27.7%
5.8M
SG&A
3.1M
+35.0%
2.3M
-36.3%
3.6M
+4.5%
3.4M
+4.1%
3.3M
Operating Income
-6521087
+2.3%
-6674708
+18.0%
-8140142
-6.8%
-7623351
+16.3%
-9105758
EBITDA
-6515628
+2.3%
-6669249
+18.0%
-8134683
-6.6%
-7627562
+16.2%
-9100299
Net Income
-7349056
+2.8%
-7562919
+16.1%
-9009411
+4.5%
-9434208
-11.1%
-8488967
EPS (Basic)
$-0.13
+7.1%
$-0.14
+26.3%
$-0.19
+9.5%
$-0.21
+0.0%
$-0.21
EPS (Diluted)
$-0.13
+7.1%
$-0.14
+26.3%
$-0.19
+9.5%
$-0.21
+0.0%
$-0.21
Shares (Diluted)
55.5M
+6.2%
52.2M
+11.5%
46.9M
+2.1%
45.9M
+13.3%
40.5M
PDS Biotechnology (PDSB) โ€” Financials